Several lines of evidence suggest that incretin-based therapies, including GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, may stabilize or reverse the β-cell loss and slow or prevent the progression of prediabetes (35–37). This evidence concerns the gene GLP1R and prediabetes syndrome.